Page 31 - CIBEREHD2016-ENG

CIBERHEP.
Chronic Hepatitis B Platform
The CIBERHEP chronic hepatitis B platform is a cooperation scheme between the CIBER and the Asociación Española para el Estudio del Hígado (AEEH). This is currently the main database for patients being treated for chronic hepatitis B in Spain: in 2016 the data for 1427 patients monitored at 29 centres in 9 different autonomous communities was recorded.
In 2016, the studies performed from this data focussed above all on safety and effectiveness in front-
line therapeutic options against the hepatitis B virus, entecavir (ETV) and tenofovir (TDF), and on the progression to hepatocellular carcinoma (HCC) of the patients undergoing treatment with these antiviral agents. In this respect the cases in which HCC was developed during antiviral treatment were analysed to compare these with the ones predicted by
the PAGE-B score, for prediction of the development of HCC in Caucasian patients treated with ETV and TDF. The aim of this study was to validate this system of scoring in the Spanish population of chronic hepatitis B patients in antiviral treatment. The results of the study were presented as an oral paper at the 41 Congreso Anual de la AEEH (Madrid, 17-19 February 2016) and as a poster at the 51 Annual Congress of the European Association for the Study of the Liver (EASL) (Barcelona, 13–17 April 2016).This study was later extended with the analyses of the efficacy and renal safety of ETV and TDF in this cohort of patients for the validation of the PAGE-B score. The final results of the article were accepted for publication in the Digestive Diseases and Sciences journal [Riveiro- Barciela, M., Tabernero, D., Calleja, J.L. et al. Dig Dis Sci (2017). doi:10.1007/s10620-017-4448-7].
The renal level safety of ETV and TDF was also studied in patients with chronic hepatitis B over 65 years of age in routine clinical practice. The results of this study were presented as a poster at the 67 Annual Congress of the American Association for the Study of Liver Diseases (AASLD) (Boston, USA, 11-15 November 2016).
Lastly, the updating of the database and its associated web page were completed, thus extending the data collected to carry out more exhaustive studies on the monitoring of patients in antiviral treatment with ETV and TDF, especially focussing on their safety and side-effects, at the same time as recording this data.
CIC bioGUNE.
Plataform for Genomics, Proteomics,
Metabolomics and Gene Silencing
Genomics Platform
In 2016 the genome analysis platform carried out 77 characterisation services with a total number of 5786 samples for the description of their genotyping, transcriptomics, epigenomics or metagenomics. The platform also took part in 1 public tender for services, which meant a total sum invoiced of 70,000.00€.
As technological progress, the platform completed the adjustment of massive sequencing protocols with Oxford Nanopore Technologies (The MinION) technology.
Over this period. 4 articles were published in journals of international impact on research carried out in cooperation projects, and in June 2016, they published a book entitled “Field Guidelines for Experimental Genetic Designs in High-Throughput Sequencing”, as editors and authors of one of its chapters (8000 purchases of its chapters reissued in its first 7 months).
EHD
Platforms 31